TD Asset Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

TD Asset Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,517	Closed	-$187K	–	1389
2017 Q1	$187K	Sell	1,517 -1,341	-47%	-$176K	﹤0.01%	1378
2016 Q4	$389K	Sell	2,858 -290	-9%	-$51.5K	﹤0.01%	1240
2016 Q3	$626K	Sell	3,148 -270	-8%	-$46.5K	﹤0.01%	1114
2016 Q2	$443K	Sell	3,418 -30	-0.9%	-$3.34K	﹤0.01%	1152
2016 Q1	$322K	Sell	3,448 -120	-3%	-$13.1K	﹤0.01%	1213
2015 Q4	$723K	Sell	3,568 -1,260	-26%	-$225K	﹤0.01%	1013
2015 Q3	$701K	Buy	4,828 +1,438	+42%	+$264K	﹤0.01%	995
2015 Q2	$721K	Buy	3,390 +1,920	+131%	+$471K	﹤0.01%	1034
2015 Q1	$341K	Buy	1,470 +420	+40%	+$102K	﹤0.01%	1210
2014 Q4	$242K	Buy	+1,050	New	+$225K	﹤0.01%	1285

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

TD Asset Management's BLCM Position: Q2 2017 in Review

TD Asset Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2017, closing a stake of 1,517 shares — an estimated $187K sold.

TD Asset Management first reported a position in BLCM in Q4 2014 and held it in 10 quarters. The position peaked at $723K in Q4 2015. 84 funds tracked by Wall St. Rank hold BLCM as of Q2 2017.

TD Asset Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
TD Asset Management sold 1,517 Bellicum Pharmaceuticals, Inc. shares in Q2 2017, an estimated $187K.
TD Asset Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 10 quarters.
TD Asset Management's Bellicum Pharmaceuticals, Inc. position peaked at $723K in Q4 2015.
84 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2017.

Based on TD Asset Management's 13F filing for Q2 2017, filed 1 Aug 2017.